Segments Covered in the global monoclonal antibodies market report:
The global monoclonal antibodies market is segmented based on treatment type, therapy area, route of administration, distribution channel, region as follows:
- Treatment Type (Revenue, USD Billion; 2022–2030)
- Biologics
- Biosimilar
- Others
- Therapy Area (Revenue, USD Billion; 2022–2030)
- Oncology
- Neurological Diseases
- Cardiovascular Diseases
- Infectious Diseases
- Musculoskeletal Diseases
- Hematologic Diseases
- Others
- Route of Administration (Revenue, USD Billion; 2022–2030)
- Oral
- Injectable
- Others
- Distribution Channel (Revenue, USD Billion; 2022–2030)
- Hospital Pharmacies
- Specialty Pharmacies
- Online Pharmacies
- Region (Revenue, USD Billion; 2022–2030)
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- Japan
- South Korea
- India
- ASEAN
- Rest of APAC
- North America
-
- Latin America
- Brazil
- Mexico
- Rest of LATAM
- Middle East & Africa
- Saudi Arabia
- UAE
- Rest of MEA
- Latin America
Frequently Asked Questions
The current market size of the monoclonal antibodies industry is US$ 210.06 billion in 2023.
Rising prevalence of chronic diseases, high demand for biologics, and increasing R&D activities in genomics are contributing significantly to the growth of the Monoclonal Antibodies market.
High cost of monoclonal antibody therapies and limited access to care in developing countries are the key factors hampering the growth of the Monoclonal Antibodies Market.
The leading component segment in the Monoclonal Antibodies Market is human monoclonal antibodies.
Roche, AbbVie, Johnson & Johnson, Pfizer, Bristol-Myers Squibb, Eli Lilly, Merck are some of the major players operating in the Monoclonal Antibodies Market.
The monoclonal antibodies market is expected to grow at a compound annual growth rate (CAGR) of 11.6% from 2023 to 2030, reaching a market size of US$ 359.2 billion by 2030.